Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis...

Emisphere Announces Recruitment of Novartis Phase III Study for Oral
Osteoporosis Treatment
Phase III Study to Explore the Effects of Eligen(R) Delivery Technology and
Salmon Calcitonin on Vertebral Fractures in Postmenopausal Women

CEDAR KNOLLS, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) announced today that Novartis Pharma AG has
finished recruitment for a multi-center Phase III study exploring the safety
and efficacy of Salmon Calcitonin and Emisphere's proprietary Eligen(R)
Technology in the treatment of vertebral fractures in postmenopausal women
aged 60-80 with osteoporosis. The last of 4,500+ patients was recruited in the
final week of June, and the three-year study will be conducted in North and
South America, Europe and Asia.
Osteoporosis is a disease associated with a gradual thinning and weakening
of the bones, occurring most frequently in women after menopause. Thinner and
weaker bones are increasingly susceptible to fractures. Untreated
postmenopausal osteoporosis can lead to chronic back pain, disabling
fractures, and lost mobility.
"This Phase III study provides yet another application of our Eligen(R)
Technology in the fight against osteoporosis. Safe, effective and rapid
treatment will make a difference in the lives of millions of American women
who are afflicted with the disease," said Michael V. Novinski, President and
Chief Executive Officer of Emisphere.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company that focuses
on a unique and improved delivery of therapeutic molecules using its Eligen(R)
Technology. These molecules and compounds could be currently available or in
development. Such molecules are usually delivered by injection; in many cases,
their benefits are limited due to poor bioavailability, slow on-set of action
or variable absorption. The Eligen(R) Technology can be applied to the oral
route of administration as well other delivery pathways, such as buccal,
rectal, inhalation, intra-vaginal or transdermal. The website is:
www.emisphere.com.
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by representatives
of Emisphere relating to matters that are not historical facts (including
without limitation those regarding the timing or potential outcomes of
research collaborations or clinical trials, any market that might develop for
any of Emisphere's product candidates and the sufficiency of Emisphere's cash
and other capital resources) are forward-looking statements that involve risks
and uncertainties, including, but not limited to, the likelihood that future
research will prove successful, the likelihood that any product in the
research pipeline will receive regulatory approval in the United States or
abroad, the ability of Emisphere and/or its partners to develop, manufacture
and commercialize products using Emisphere's drug delivery technology,
Emisphere's ability to fund such efforts with or without partners, and other
risks and uncertainties detailed in Emisphere's filings with the Securities
and Exchange Commission, including those factors discussed under the caption
"Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615)
filed on March 5, 2007 and our Quarterly Report on Form 10-Q for the quarter
ended March 31, 2007, filed on May 7, 2007.
For further information contact:
Bob Madison, Senior Director Corporate Communications
973-532-8001 or bmadison@emisphere.com

Adam Friedman, Adam Friedman Associates
212-981-2529, extension 18 or adam@adam-friedman.com

SOURCE Emisphere Technologies, Inc.

Bob Madison, Senior Director Corporate Communications, +1-973-532-8001,
bmadison@emisphere.com; or Adam Friedman of Adam Friedman Associates,
+1-212-981-2529, extension 18, adam@adam-friedman.com